Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 31%
Sell 15%
Strong Sell 0%

Bulls say

CME Group has demonstrated a robust revenue growth of approximately 8.1% year-over-year, reaching total revenue of $1,649 million, while its Market Data segment has experienced an impressive growth rate of 14.5%, driven by an influx of new users and effective pricing strategies. The company's commitment to returning value to shareholders is evident, as it has increased its quarterly dividend payments for 14 consecutive years, supported by strong free cash flow generation. Furthermore, the average daily volume (ADV) has exhibited a compound annual growth rate of over 7% from FY16 through FY24, showcasing continuous customer demand and product innovation, which are expected to further enhance revenue growth moving forward.

Bears say

CME Group faces significant headwinds that negatively impact its financial outlook, including a projected 10% decline in FY27 earnings per share (EPS) and anticipated revenue growth of only 5.4% year-over-year, which falls short of the consensus estimate of 6.0%. Heightened competitive threats and a decline in trading volume for interest rate futures, due to a forthcoming rate-cutting cycle, exacerbate concerns over pricing pressures and limited margin improvement. Furthermore, increased regulatory scrutiny could further diminish trading volumes, adding to the company's challenges in maintaining its revenue and profitability amidst an evolving market landscape.

CME Group (CME) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 15% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 13 analysts, CME Group (CME) has a Buy consensus rating as of Mar 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $295.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $295.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.